12 November 2025
12 November 2025
Dr Richard Pazdur replaces George Tidmarsh, who resigned earlier this month amid controversy.
After two decades of use, warnings for breast cancer and cardiovascular disease will be removed from hormonal treatments for menopause.
If successful in the Phase III trial, VK2735 would enter direct competition with established dual agonists such as Eli Lilly’s tirzepatide.
Administered once weekly via subcutaneous injection, semaglutide offers efficacy and durability advantages across multiple metabolic and cardiovascular indications.
As more individuals with T1D develop features of insulin resistance, new tools are needed to identify those at highest risk.
US Phase I clinical trial data reveal dose-dependent activity of LYL273 in 12 patients.
Preliminary outcomes from the safety run-in cohort will be presented at the American Society of Hematology 2025 Annual Meeting.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
